non-small cell lung cancer
Conditions
Interventions
Group one (Non-squamous cell carcinoma: camrelizumab + weak chemotherapy + Endo):None
Group two (Squamous cell carcinoma: camrelizumab + weak chemotherapy + endo):None
Sponsors
Shandong Provincial Public Health Clinical Center
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Age= 18 years old and = 75 years old; 2. Patients with histologically or cytologically confirmed non-small cell lung cancer according to the International Association for the Study of Lung Cancer and the American Joint Committee on Cancer Classification, 8th edition of the TNM staging classification of lung cancer; 3. Received camrelizumab combined with weak chemotherapy and first-line treatment with Endu 4. Subjects voluntarily joined this study, signed the informed consent form, had good compliance, and cooperated with follow-up.
Exclusion criteria
Exclusion criteria: 1. Patients who have been treated with other immunological drugs or therapies at the same time; 2. Patients who are participating in other interventional studies; 3. Patients with other malignant tumors at the same time; 4. Patients with missing data and information related to key studies. 5. Confirmed pregnancy and lactating females.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safty; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression free survival;Overall survival;Objective response rate;Disease control rate;Duration of remission;Serious adverse event;Immune-related adverse events; | — |
Countries
China
Contacts
Public ContactLiu Jie
Shandong Provincial Public Health Clinical Center, Licheng District, Jinan City, Shandong Province
Outcome results
None listed